ConductScience.org, home

Paper33682011

Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer.

Moriyama J and 7 others. Surg Today, 2021. Cited by 30 papers, by iCite.

Cite this record

ConductScience Library. Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer. Papers, record 33682011. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33682011

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer.
PubMed
Journal
Surg Today
PubMed
Year
2021
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
30
iCite
Relative citation ratio, by iCite
1.87
iCite
Revised in PubMed
2026-10-10
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Moriyama JJin
2Oshima YYoko
3Nanami TTatsuki
4Suzuki TTakashi
5Yajima SSatoshi
6Shiratori FFumiaki
7Funahashi KKimihiko
8Shimada HHideakihttps://orcid.org/0000-0002-1990-8217

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Biomarkers, TumorMajor topic
CA-19-9 AntigenMajor topic
Carcinoembryonic AntigenMajor topic
Neoplasm Recurrence, LocalMajor topic
Stomach NeoplasmsMajor topic
Female
Gastrectomy
Humans
Lymph Node Excision
Male
Prognosis
Retrospective Studies
Survival Rate

Source PubMed

Download CSV of topics

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123564806Better outcomes by monitoring tumour dynamics using sensitive tumour markers in patients with recurrent gastric cancer.Anticancer Res2013https://conductscience.org/library/papers/23564806PubMed
227097114Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma.Oncotarget2016https://conductscience.org/library/papers/27097114PubMed
330923789Diagnostic impact of high serum midkine level in patients with gastric cancer.Ann Gastroenterol Surg2019https://conductscience.org/library/papers/30923789PubMed
423208313Investigation of the freely available easy-to-use software 'EZR' for medical statistics.Bone Marrow Transplant2013https://conductscience.org/library/papers/23208313PubMed
527147574Combined preoperative concentrations of CEA, CA 19-9, and 72-4 for predicting outcomes in patients with gastric cancer after curative resection.Oncotarget2016https://conductscience.org/library/papers/27147574PubMed
632560392CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer.J Clin Med2020https://conductscience.org/library/papers/32560392PubMed
726576068Clinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-Analysis.Dis Markers2015https://conductscience.org/library/papers/26576068PubMed
829100454Peritoneal recurrence in gastric cancer following curative resection can be predicted by postoperative but not preoperative biomarkers: a single-institution study of 320 cases.Oncotarget2017https://conductscience.org/library/papers/29100454PubMed
925854347Preoperative serum CEA and CA19-9 in gastric cancer--a single tertiary hospital study of 1,075 cases.Asian Pac J Cancer Prev2015https://conductscience.org/library/papers/25854347PubMed
1029926189The association of the lymph node ratio and serum carbohydrate antigen 19-9 with early recurrence after curative gastrectomy for gastric cancer.Surg Today2018https://conductscience.org/library/papers/29926189PubMed
1114520526The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.Gastric Cancer2003https://conductscience.org/library/papers/14520526PubMed
1232458231Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery.Surg Today2020https://conductscience.org/library/papers/32458231PubMed
1327566604The characteristics of the serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer cases.Surg Today2017https://conductscience.org/library/papers/27566604PubMed
1430984347Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer.World J Gastrointest Oncol2019https://conductscience.org/library/papers/30984347PubMed
1532490341Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers.Ann Gastroenterol Surg2020https://conductscience.org/library/papers/32490341PubMed
1631820210Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA.Int J Clin Oncol2020https://conductscience.org/library/papers/31820210PubMed
1729121872Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.BMC Cancer2017https://conductscience.org/library/papers/29121872PubMed
1828441659Perioperative Serum Carcinoembryonic Antigen Levels Predict Recurrence and Survival of Patients with Pathological T2-4 Gastric Cancer Treated with Curative Gastrectomy.Dig Surg2018https://conductscience.org/library/papers/28441659PubMed
1930574476Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 72-4 in Gastric Cancer: Is the Old Band Still Playing?Gastrointest Tumors2018https://conductscience.org/library/papers/30574476PubMed
2025580353The value of postoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the early detection of gastric cancer recurrence after curative resection.J Gastric Cancer2014https://conductscience.org/library/papers/25580353PubMed

See all 22 referencesDownload CSV of references

Cited by24

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.

PMIDTitleJournalYearIn PapersSource
42796292
Intermediate-Term Oncological, Anastomotic and Nutritional Outcomes of the Sutureless L-Shaped Esophagojejunostomy with Endoscopic Assistance (SLEJ) in Totally Laparoscopic Total Gastrectomy: A Follow-Up Analysis of This Technique.
Medicina (Kaunas)2026https://conductscience.org/library/papers/42796292PubMed
42736302Value of preoperative peripheral blood inflammation markers in predicting prognosis after radical gastric cancer surgery.Sci Rep2026https://conductscience.org/library/papers/42736302PubMed
41906027CXCL12 and eotaxin are independent prognostic serum biomarkers in gastric cancer.Sci Rep2026https://conductscience.org/library/papers/41906027PubMed
41384977The prognostic value of serum lactate dehydrogenase levels in patients with carcinoembryonic antigen (CEA)- and carbohydrate antigen 19-9 (CA19-9)-negative colorectal cancer.Surg Today2026https://conductscience.org/library/papers/41384977PubMed
40877868Novel surveillance protocol for gastric cancer based on CEA: a high-volume multi-center study.BMC Cancer2025https://conductscience.org/library/papers/40877868PubMed
40673317[High PRELID1 expression promotes epithelial-mesenchymal transition in gastric cancer cells and is associated with poor prognosis].Nan Fang Yi Ke Da Xue Xue Bao2025https://conductscience.org/library/papers/40673317PubMed
40647250Nutritional and Biochemical Outcomes After Total Versus Subtotal Gastrectomy: Insights into Early Postoperative Prognosis.Nutrients2025https://conductscience.org/library/papers/40647250PubMed
40406247Clinical value of CA125, AFP, and CEA for combined diagnosis and assessment of gastric cancer prognosis.Front Oncol2025https://conductscience.org/library/papers/40406247PubMed
38884851PG I and PG II show unique value in diagnosing postoperative biochemical recurrence in patients with gastric cancer after total gastrectomy.Discov Oncol2024https://conductscience.org/library/papers/38884851PubMed
38835478Predictive Value of the Total Bilirubin and CA50 Screened Based on Machine Learning for Recurrence of Bladder Cancer Patients.Cancer Manag Res2024https://conductscience.org/library/papers/38835478PubMed
38703060Human circular RNA hsa_circ_0000231 clinical diagnostic effectiveness as a new tumor marker in gastric cancer.Cancer Rep (Hoboken)2024https://conductscience.org/library/papers/38703060PubMed
38444686Development and validation of serological dynamic risk score to predict outcome in gastric cancer with adjuvant chemotherapy: a multicentre, longitudinal, cohort study.Front Oncol2024https://conductscience.org/library/papers/38444686PubMed
38263014CA19‑9 is a significant prognostic factor in stage III gastric cancer patients undergoing radical gastrectomy.BMC Surg2024https://conductscience.org/library/papers/38263014PubMed
38166693Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients.BMC Cancer2024https://conductscience.org/library/papers/38166693PubMed
37839102Humanized Anti-Carcinoembryonic Antigen Antibodies Brightly Target and Label Gastric Cancer in Orthotopic Mouse Models.J Surg Res2024https://conductscience.org/library/papers/37839102PubMed
37728233Development and Validation of Tumor Marker Indices in Advanced Gastric Cancer Patients.Cancer Control2023https://conductscience.org/library/papers/37728233PubMed
37658871Prognostic factor in patient with recurrent pancreatic adenocarcinoma.Langenbecks Arch Surg2023https://conductscience.org/library/papers/37658871PubMed
37569566Using Normalized Carcinoembryonic Antigen and Carbohydrate Antigen 19 to Predict and Monitor the Efficacy of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.Int J Mol Sci2023https://conductscience.org/library/papers/37569566PubMed
37545214LncRNA ARAP1-AS1 contributes to lung adenocarcinoma development by targeting miR-8068 to upregulate CEACAM5.Cancer Biomark2023https://conductscience.org/library/papers/37545214PubMed
37256148Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression.Front Immunol2023https://conductscience.org/library/papers/37256148PubMed

See all 24 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CEACAM1634PubTator's text mininghttps://conductscience.org/library/genes/634NCBI Gene
CEACAM31084PubTator's text mininghttps://conductscience.org/library/genes/1084NCBI Gene
CEACAM51048PubTator's text mininghttps://conductscience.org/library/genes/1048NCBI Gene
GDF159518PubTator's text mininghttps://conductscience.org/library/genes/9518NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33682011

GET https://conductscience.org/api/papers/v1/33682011/references?page=2